These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33111401)

  • 1. Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease.
    Buchheit BM; Joslin T; Turner HN; Wong TE
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28766. PubMed ID: 33111401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.
    Leyde S; Suen L; Pratt L; DeFries T
    J Gen Intern Med; 2022 Apr; 37(5):1281-1285. PubMed ID: 34993878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Induction of Buprenorphine/Naloxone for Chronic Pain Using a Microdosing Regimen: A Case Report.
    Lee DS; Hann JE; Klaire SS; Nikoo M; Negraeff MD; Rezazadeh-Azar P
    A A Pract; 2020 Jan; 14(2):44-47. PubMed ID: 31770128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization.
    David MS; Jones J; Lauriello A; Nnake I; Plazas Montana M; Lasko K; Buri-Nagua C; Olagbaju Y; Williams E; Sears M; Salzberg B; Lanzkron SM; Carroll CP
    Am J Hematol; 2022 Nov; 97(11):1435-1442. PubMed ID: 36053825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
    Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
    Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.
    Robbins JL; Englander H; Gregg J
    J Am Board Fam Med; 2021 Feb; 34(Suppl):S141-S146. PubMed ID: 33622829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of chronic pain and opioid dependence with buprenorphine/naloxone.
    Chang HM; Chen LY
    Psychiatry Clin Neurosci; 2018 Jun; 72(6):454. PubMed ID: 29573109
    [No Abstract]   [Full Text] [Related]  

  • 13. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B; Levin J; Chang HY; Jones C; Alexander GC
    JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Buprenorphine-A Treatment for Psychological Pain and Suicidal Ideation?
    Benhamou OM; Lynch S; Klepacz L
    Am J Addict; 2021 Jan; 30(1):80-82. PubMed ID: 32662143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes.
    DeWeese JP; Krenz JR; Wakeman SE; Peckham AM
    Subst Abus; 2021; 42(4):506-511. PubMed ID: 33945452
    [No Abstract]   [Full Text] [Related]  

  • 19. Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.
    Rozylo J; Mitchell K; Nikoo M; Durante SE; Barbic SP; Lin D; Mathias S; Azar P
    Addict Sci Clin Pract; 2020 Jan; 15(1):2. PubMed ID: 31941547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of an ED High-Dose Opioid Protocol for Sickle Cell Disease Pain.
    Tanabe P; Martinovich Z; Buckley B; Schmelzer A; Paice JA
    J Emerg Nurs; 2015 May; 41(3):227-35. PubMed ID: 25241635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.